Device Trial Radar · NCT07091773
A Clinical Trial to Evaluate the Safety and Effectiveness of OLIZ, a Photobiomodulation Medical Device for Surgical Site Pain Relief in Patients After Total Knee Arthroplasty
Last checked: Nov 19, 2026Latest source record: Jul 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
68
Planned (sponsor's estimate)
Start
Aug 20, 2025
Primary completion
Jan 30, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- LTBIO Co., Ltd.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Inje University; InjeUniversityIlsanPaikHospital; Gangnam Severance Hospital; National Medical Center, Seoul; National Health Insurance Service Ilsan Hospital; Korea University Anam Hospital; Samsung Medical Center; The Catholic University of Korea Uijeongbu St.Marys Hostpial
- First posted
- Jul 29, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 19 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Clinical Trial to Evaluate the Safety and Effectiveness of OLIZ, a Photobiomodulation Medical Device for Surgical Site Pain Relief in Patients After Total Knee Arthroplasty
Conditions
- Postoperative Pain Management During Rehabilitation in Patients Undergoing Total Knee Arthroplasty
Interventions
OLIZ Photobiomodulation DeviceDevice
OLIZ device utilizes dual-wavelength technology combining specific red (660nm) and near-infrared (850nm) light parameters optimized for post-surgical tissue healing. The device features controlled power density, precise treatment duration protocols, and targeted application to knee arthroplasty surgical sites. Treatment parameters include specific irradiance levels, treatment session duration of 15 minutes, and 3 times of daily application frequency designed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in VAS Pain ScoreTime frame: Baseline and 11 weeks post-baseline
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.